Adendra Therapeutics develops dendritic cell‑focused immunotherapies for solid tumors and autoimmune diseases. By engineering vectors that deliver tumor‑specific or autoantigen peptides together with proprietary adjuvant blends, the platform enhances antigen presentation and steers immune responses for either tumor eradication or immune tolerance. The modular, GMP‑compatible system enables rapid creation of personalized vaccine candidates and combination‑ready formats for pharmaceutical partners.
Funding
$53M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current immunotherapies for solid tumors and autoimmune diseases often suffer from limited efficacy, off‑target effects, and insufficient activation of the immune system, leaving many patients without durable treatment options.
Solution
Adendra Therapeutics leverages recent advances in dendritic cell biology to create next‑generation immunomodulatory therapies. By engineering dendritic cell‑focused platforms, the company aims to enhance antigen presentation and precisely steer immune responses toward tumor eradication or immune tolerance in autoimmunity. Their approach integrates novel antigen‑loading strategies, tailored adjuvant formulations, and scalable manufacturing processes to produce therapeutics that can be administered systemically or locally. Preclinical data suggest improved potency and safety compared with existing checkpoint inhibitors and broad‑acting immunosuppressants.
Target Audience
Primary customers are pharmaceutical companies and clinical research organizations developing immunotherapies for solid cancers and autoimmune disorders, as well as oncology and rheumatology specialists seeking novel treatment options.
Features
- Engineered dendritic cell‑targeted vectors that deliver tumor‑specific or autoantigen peptides
- Proprietary adjuvant blends designed to boost dendritic cell activation without systemic cytokine release
- Modular platform enabling rapid generation of personalized vaccine candidates
- Combination‑ready formats for pairing with checkpoint blockade or conventional immunosuppressants
- Scalable GMP‑compatible production pipeline for both solid‑tumor and autoimmune indications